Daklinza (daclatasvir)
Share
Follow Us
What is Daklinza?
UPDATE: Bristol Myers Squibb discontinued Daklinza effective June 2019.
On July 24, 2015 the U.S. Food and Drug Administration approved the prescription medication Daklinza™ (daclatasvir) a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir for the treatment of chronic HCV genotype 3 infection.
Daklinza is available in both 30 mg and 60 mg forms containing the active ingredient daclatasvir.
Last Updated: June 2019
FDA Approved Daklinza (Daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3. http://news.bms.com/press-release/fda-approves-daklinza-daclatasvir-treatment-patients-chronic-hepatitis-c-genotype-3, Bristol-Myers Squibb Company. Retrieved July 27, 2015.
Financial Help Info for Daklinza (daclatasvir) . http://www.daklinza.bmscustomerconnect.com/support, Bristol-Myers Squibb Company. Retrieved July 27, 2015.
Highlights of Prescribing Information - DAKLINZA. http://packageinserts.bms.com/pi/pi_daklinza.pdf, Bristol-Myers Squibb Company. Retrieved July 27, 2015.
Patient Support Connect. http://www.patientsupportconnect.bmscustomerconnect.com/, Bristol-Myers Squibb Company. Retrieved July 27, 2015.
